ITGA6 and cancer: As indicated in the Supplementary Table 2, we found ITGA3 significantly associated with primary therapy outcome (p < 0.0001), ITGA6 significantly associated with OS status (p = 0.026), ITGB4 significantly associated with cancer status (p = 0.042) and tumor residual (p = 0.024), ITGB8 significantly associated with chemotherapy (p = 0.020).